Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Summary: Contrary to long-standing beliefs, T cells—key immune cells—have been discovered in the healthy brains of both mice and humans. These cells, previously thought to only enter the brain during ...

Bispecific T cell engagers (TcEs) are immunotherapeutic drugs that trigger the destruction of cancer cells by linking T cells to cancer cells through specific surface molecules (antigens). We designed ...

Integrated, automated facility will unlock next-generation, commercial-scale cell therapy manufacturing in Japan IDMO Smart Factory manufacturing capabilities will accelerate patient access for CAR-T ...

with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE ...

Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.

with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics.

The agreement grants Juri exclusive global rights to a development-ready T-cell engager targeting kallikrein-related peptidase 2 (KLK2) and CD3 for the treatment of metastatic prostate cancer.